Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial.
about
Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial.Emerging treatment options for ovarian cancer: focus on rucaparib.Poly (ADP-ribose) polymerase inhibitors in the management of ovarian cancer.Reprogramming T-cells for adoptive immunotherapy of ovarian cancer.The development of PARP as a successful target for cancer therapy.Management of hereditary breast and ovarian cancer.Clinical trials in gynecologic oncology: Past, present, and future.Update on relapsed ovarian cancer treatment: from new consensus to daily clinical practice.Ovarian Cancers: Genetic Abnormalities, Tumor Heterogeneity and Progression, Clonal Evolution and Cancer Stem Cells.PARP inhibitors as potential therapeutic agents for various cancers: focus on niraparib and its first global approval for maintenance therapy of gynecologic cancers.The HRD Decision-Which PARP Inhibitor to Use for Whom and When.PARP inhibitors in platinum-sensitive high-grade serous ovarian cancer.PARP inhibitors: Clinical utility and possibilities of overcoming resistance.Incorporating Biomarker Stratification into STAMPEDE: an Adaptive Multi-arm, Multi-stage Trial Platform.A PET imaging agent for evaluating PARP-1 expression in ovarian cancer.PARP inhibitors for homologous recombination-deficient prostate cancer.Deoxyribonucleic Acid Damage and Repair: Capitalizing on Our Understanding of the Mechanisms of Maintaining Genomic Integrity for Therapeutic Purposes.A phase 1 dose-escalation study of veliparib with bimonthly FOLFIRI in patients with advanced solid tumours.Next-generation Sequencing Reveals Recurrent Somatic Mutations in Small Cell Neuroendocrine Carcinoma of the Uterine Cervix.Major clinical research advances in gynecologic cancer in 2017.Spotlight on olaparib in the treatment of BRCA-mutated ovarian cancer: design, development and place in therapy.Risk of severe hematologic toxicities in cancer patients treated with PARP inhibitors: results of monotherapy and combination therapy trials.Rucaparib: a novel PARP inhibitor for BRCA advanced ovarian cancer.Breakthroughs in the treatment of advanced squamous-cell NSCLC: not the neglected sibling anymore?Rucaparib in ovarian cancer: an update on safety, efficacy and place in therapy.Practice guidelines for management of ovarian cancer in Korea: a Korean Society of Gynecologic Oncology Consensus Statement.Dancing with the DNA damage response: next-generation anti-cancer therapeutic strategies.Risk of selected gastrointestinal toxicities associated with poly (ADP-ribose) polymerase (PARP) inhibitors in the treatment of ovarian cancer: a meta-analysis of published trialsA practical guide to understanding, using and including patient reported outcomes in clinical trials in ovarian cancerEvolution of genetic assessment for BRCA-associated gynaecologic malignancies: a Canadian multisociety roadmapLow-grade Serous Ovarian CarcinomaExploring the Role of Fallopian Ciliated Cells in the Pathogenesis of High-Grade Serous Ovarian CancerOptimizing poly (ADP-ribose) polymerase inhibition through combined epigenetic and immunotherapyPoly (ADP-ribose) Polymerase Inhibitors in the Management of Ovarian Cancer: A Drug Class ReviewThe efficacy and safety of olaparib in the treatment of cancers: a meta-analysis of randomized controlled trialsTargeted treatment of advanced ovarian cancer: spotlight on rucaparib
P2860
Q46270437-A96E2DD0-6A26-4030-9999-C9B3708F9575Q47107471-A1D2C1A6-8187-4887-8535-9A1A4449DCC5Q47192515-DBC2559E-DCBA-408B-ADD1-D90B0F1BB8B1Q47201278-13FC3601-9CC2-4C65-B458-AF9C58EA7965Q47278103-7D8E63E1-009E-4D17-88F4-D2A3010FC4B1Q47399250-D3D8A5DA-AD67-446F-A7BC-60FE9F20482FQ47796770-D12391AA-8468-4D1F-BA35-0F2459915EFFQ47903356-486080C1-A6B7-4723-9A3C-AFDDA4B61746Q48124146-F7FF06C1-BDBD-43DC-B5C1-6487227D785EQ48164214-4E6CFF13-DCAB-428A-B110-D158CA1EEF27Q49643008-A357AAA7-7E89-4018-835F-74E947D7EF04Q49723005-081F25CB-2CBD-4B69-B999-630F9B57CCACQ50076626-8BF44633-2B1A-4768-A9CD-E85350758409Q50099775-28CE0185-BC23-4827-838C-84B2F6481628Q52430620-6698628F-30E1-4CF6-9815-1C20E87C8CC9Q52623144-DD32398C-DCCE-49BE-96E8-F5397CA6467DQ52720061-5E6B0D11-53AE-4205-941D-ED86BBE4B363Q52807922-7A1B7E5C-57E7-4E89-B2B9-D0FB5500AC24Q54096033-38F9A82B-E73A-4BB0-A5DB-68AA2DEE61A8Q54952356-EEC4B6A9-CDB3-4819-8A2B-A04D8077C505Q55041688-3F5C8CB7-872C-43E5-B666-B02F05E5E64DQ55044880-20EB9F7D-D0E4-4E5A-8C38-D727ED162F5BQ55211683-B9FCA5BE-CD52-48F9-86C6-39D2B1F8A9C4Q55341383-3338EC80-8F4F-471B-88F9-A1D7982C14F6Q55416207-F0CDC941-3CCA-4E77-8049-9A27AF5B6FCEQ55493644-0A774E42-3A2C-4FF5-91A4-A134CB8B484CQ55710290-87C173F3-2F4B-44FA-8D39-FF7CD758AC5FQ57074340-69C7DF58-E963-4071-8971-3E837EDE1E52Q57164771-8774A16A-C050-4998-AD70-B161E2456885Q57907545-507E6039-5987-4C57-91CA-7FD256A4F7D1Q58592773-9A42B4CA-06B6-457B-9868-4295A10E5CCBQ58704255-A2CAB208-CDAA-4120-A5AD-359D039E9F02Q58719363-3D01CC99-048F-4AF3-A513-8319098D07D7Q58777513-E5658B62-CEC6-46FB-B1F4-EE8436B4F6CDQ58790609-FFF9D337-68A5-46E9-9ED1-5DD2905F10CBQ59125756-E0083628-7809-48A9-839A-7DBEC71A6635
P2860
Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial.
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年学术文章
@wuu
2017年学术文章
@zh-cn
2017年学术文章
@zh-hans
2017年学术文章
@zh-my
2017年学术文章
@zh-sg
2017年學術文章
@yue
2017年學術文章
@zh
2017年學術文章
@zh-hant
name
Olaparib tablets as maintenanc ...... ebo-controlled, phase 3 trial.
@en
type
label
Olaparib tablets as maintenanc ...... ebo-controlled, phase 3 trial.
@en
prefLabel
Olaparib tablets as maintenanc ...... ebo-controlled, phase 3 trial.
@en
P2093
P921
P1433
P1476
Olaparib tablets as maintenanc ...... ebo-controlled, phase 3 trial.
@en
P2093
Amit M Oza
Andrés Poveda
Elizabeth S Lowe
Frédéric Selle
Isabelle Ray-Coquard
Jacob Korach
Jonathan A Ledermann
Keiichi Fujiwara
Michael Friedlander
P356
10.1016/S1470-2045(17)30469-2
P577
2017-07-25T00:00:00Z